NCCN melanoma guidelines revised to reflect emerging data for novel agents, treatment regimens

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
First-line systemic therapy
  • For unresectable or metastatic disease, recommended treatment options include checkpoint immunotherapy, BRAF-targeted therapy for patients with BRAF-mutated disease, or clinical trial.
  • Checkpoint immunotherapy options include anti-programmed cell death protein-1 (PD-1) monotherapy with pembrolizumab (category 2A), nivolumab (category 1), or nivolumab/ipilimumab combination therapy (category 2A).
  • Single-agent ipilimumab monotherapy is no longer recommended by the National Comprehensive Cancer Network (NCCN) as a first-line therapy option: results from the CheckMate 067 phase 3 trial demonstrated better outcomes with anti-PD-1 monotherapy or nivolumab/ipilimumab combination therapy vs ipilimumab alone.
  • In BRAF-mutant metastatic disease, first-line targeted therapies include BRAF/MEK inhibitor combination therapy with dabrafenib/trametinib or vemurafenib/cobimetinib, or single-agent BRAF inhibitor therapy with vemurafenib or dabrafenib. All are category 1 recommendations based on results from phase 3 trials...